Research graph
References from Time-of-day administration of immune checkpoint inhibitors: current clinical evidence and future directions for breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Overall survival with pembrolizumab in early-stage triple-negative breast cancer
10.1056/nejmoa2409932 · 2024 · External reference
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
10.1056/nejmoa2202809 · 2022 · External reference
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis
10.1016/j.esmoop.2023.102220 · 2024 · External reference
Time-of-day immunotherapy administration and outcomes in advanced cancers: a systematic review and meta-analysis
10.1001/jamanetworkopen.2026.10815 · 2026 · External reference
Time-of-day administration of immunotherapy in early-stage triple-negative breast cancer: Immune-dependent chronotherapy effects in the phase III A-BRAVE trial
10.1200/jco.2026.44.16_suppl.1010 · 2026 · External reference
Timing of neoadjuvant pembrolizumab infusion and pathologic complete response among patients with triple-negative breast cancer receiving the KEYNOTE-522 regimen
2025 · External reference
The mammalian circadian timing system: organization and coordination of central and peripheral clocks
10.1146/annurev-physiol-021909-135821 · 2010 · External reference
Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses
10.1016/j.immuni.2016.12.011 · 2017 · External reference
Dendritic cells direct circadian antitumour immune responses
10.1038/s41586-022-05605-0 · 2023 · External reference
Cortisol and epinephrine control opposing circadian rhythms in T cell subsets
10.1182/blood-2008-11-190769 · 2009 · External reference
PD-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · 2014 · External reference
Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy
10.1016/j.cell.2024.04.015 · 2024 · External reference
Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice
10.1158/1541-7786.mcr-21-0786 · 2022 · External reference
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
10.1038/s41590-024-01859-0 · 2024 · External reference
The metastatic spread of breast cancer accelerates during sleep
10.1038/s41586-022-04875-y · 2022 · External reference
LBA2 ETOP-Roche i-TIMES: Immunotherapy timing investigation on lung cancer survival
2026 · External reference
Abstract PS2-10-13: impact of infusion time-of-day of administration (ToDA) of neoadjuvant immunochemotherapy on pathological response in patients with early triple-negative breast cancer treated with KEYNOTE-522 regimen (PEMCLOCK study)
2026 · External reference
Impact of pembrolizumab infusion timing on outcomes in early-stage triple-negative breast cancer: a real-world exploratory analysis (neo-real)
10.1200/jco.2026.44.16_suppl.610 · 2026 · External reference
Association of immunotherapy infusion timing with outcomes in early-stage triple-negative breast cancer
10.1200/jco.2026.44.16_suppl.594 · 2026 · External reference
Abstract PS4-07-01: exploring the impact of circadian timing and TIL status on immunotherapy response in breast cancer
2026 · External reference
The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes
10.1016/j.ccell.2020.09.001 · 2020 · External reference
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
10.1172/jci.insight.124507 · 2018 · External reference
151TiP CIRCADIAN: circadian rhythm impact on triple-negative breast cancer (TNBC) response to neoadjuvant immunotherapy; a feasibility randomized trial
10.1016/j.esmoop.2025.104704 · 2025 · External reference
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced nonsmall cell lung cancer: a bicentric bicontinental study
10.1016/j.ebiom.2025.105607 · 2025 · External reference
Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: an In-depth chronotherapeutic study
10.1016/j.ejca.2024.113571 · 2024 · External reference
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: a retrospective multicenter study
10.1111/hepr.14171 · 2025 · External reference
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
10.1136/jitc-2023-008011 · 2024 · External reference
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
10.1016/s1470-2045(21)00546-5 · 2021 · External reference
